Forte Medical: Series A investment growth round is open

This week saw the launch of Forte Medical’s Series A investment round for growth, export and new product development. Seeking £3.5m, the company is engaging with prospective investment partners who can attract investors with an interest in evidenced, disruptive diagnostic medical devices with digital potential.

Institutional, corporate or personal investors who can assist the business long term are seen as the most promising and attractive partners. For more information, contact our CEO Giovanna Forte.

Giovanna Forte on TV

Disruptive TV: Giant Live Health Innovators

Barry Shrier, Founder of annual health innovation event Giant Live, presents the third Disruptor Giant Health Innovators TV interview featuring Giovanna Forte, CEO of Forte Medical, Francis White from AliveCor, Dr Sophie Bostoc​k of Sleepio and Etienne Bourdon from Healthy Health. Watch the half-hour programme here with Disruptive Live

The Sunday Times Maserati 100 Entrepreneurs 2018

“The entrepreneurs celebrated in this year’s Maserati 100 like to get things done’ said Sunday Times’ journalist Andrew Lynch in his introduction to this year’s list of the top 100 entrepreneurs in 2018. And that is pretty true of Forte Medical’s founder and CEO, Giovanna Forte who was featured in the People’s Choice.

Giovanna set up the company to introduce the MedTech invention of her brother, NHS GP Dr Vincent Forte to healthcare providers seeking clinical integrity and cost savings.

Dr Forte questioned the frequency of second and third appointments to cure common UTI, which were taking up valuable surgery time. His investigations concluded that unreliable urine specimens were preventing right-first-time analysis, diagnosis and targeted treatment.

Peezy Midstream delivers 98.5% accuracy, bringing integrity to basic medicine and patient care, delivering efficiency and cost savings across the healthcare pathway.

Our new products will deliver accurate specimen collection for a range of novel cancer urine tests, sports dope testing and more. The Forte Medical Specimen Collection is destined to become eponymous across diagnostic medicine.

Make sure your bladder is full | urine sample

Peezy Animation: instructions for use

How easy is Peezy? Very! Click here to see our new animation showing five simple steps that deliver right-first-time urine specimen collection. Any clinician will know that contamination can prevent or delay diagnoses; Peezy makes prompt analysis, diagnosis and treatment simple and cost effective.

Med-Tech Innovation Expo – April 2018

Giovanna Forte is one of the guest speakers at this two day and her presentation: “Urine Trouble – How Innovation is Transforming Basic Medicine” – will be given on Thursday, 26th April at 1.30 pm.

For further information about the event conference and exhibition go here

Urine sample collection

Trends in Urology & Men’s Health: solving the problem of contaminated urine samples

Despite its importance, there is no standard for urine collection. In this article the author, Professor Frank Chinegwundoh, discusses the problem of inadequate samples and describes a collection system that can help. Visit the Jan-Feb issue of Trends in Urology & Men’s Health.

Preventing Infections and Reducing AMR

An advocate and active player in healthcare infection prevention, we will participating at the Knowlex Infection Prevention and Control 2018 exhibition being held on Wednesday, 21st February 2018 at The Brewery, London EC1Y 4SD.    It is the event to hear more about  the latest research, science, innovation and discover real-world solutions in the challenge against infection prevention  Further event information can be found here.

Texas MedTech Mission Create Demand for British Goods

Paul Benton, International Director at the ABHI shares our story as to how we entered the US marketplace

Appointed sales and distribution partners, dedicated warehouse facilities and new US customers are just some of the outcomes from the UK MedTech missions to Texas.  Read more

New Forte Medical Advisory Board

Encouraged by the growing national recognition of the value of urine in diagnostic medicine, health leaders are being approached to join a new Forte Medical Advisory Board. Three leading exponents of accurate basic medicine have so far been appointed: Mike Farrar (pic) who will Chair the panel, Dr Katherine Brown and Rachel Cashman

Mike Farrar is a management consultant with 15 years of CEO experience in the NHS, having stepped down as the Chief Executive of the NHS Confederation in September 2013.  Mike has been a member of the PwC Health Industries Oversight Board and has worked on major projects across the country. Mike has also built alongside this a successful business practice working with clients such as Celesio, ROGP, ABPI, NHS Quest, NHS Leadership Academy, Health Foundation, Vanguard Health Solutions, Pfizer, CIPFA and others, as well as starting up a number of small companies aimed at promoting health innovations, and links between health and sport.

He has been Chief Executive of North West England SHA, West Yorkshire, and South Yorkshire Strategic Health Authorities and Tees Valley Health Authority and Head of Primary Care at the Department of Health. Mike remains a prominent thought leader and consultant to the NHS throughout the UK

Dr Katherine Brown is an academic based in the UK and the US with over 100 peer-reviewed publications.  She is affiliated with Cambridge and Imperial Universities and the University of Texas. With over 25 years in medical applications, she has extensive expertise in biochemistry, biophysics, infectious disease and bio/nanotechnology.

Rachel Cashman is Managing Director, The Soircas Consultancy and former Head of Clinical and Scientific Policy and Strategy, NHS England

During her 20+ years in the healthcare and life sciences sectors, Rachel has delivered large-scale change and innovation through inter-sectoral collaboration and the development of networks. At NHS England, she led the establishment of Academic Health Science Networks (AHSNs) and the process to create the first nationally commissioned network of Genomic Medicine Centres, utilising the latest scientific techniques in understanding human DNA in order to better predict, precisely diagnose and personalise treatment of cancers and rare disease.

She has worked with NHS Trusts and CCGs and their local health and care system partners to develop appropriate governance and infrastructure in response to the NHS Five Year Forward View and the emergence of the Sustainability and Transformation Partnerships. As a Board member at University Hospitals Birmingham NHS Foundation Trust and Heart of England NHS Trust, Rachel designed the strategic business case and engagement process for the proposed merger. Rachel has played an integral role in helping the NHS utilise rapid assessment protocols to evaluate potential partnership opportunities such as hospital chains, franchise models, mergers, accountable care organisations and multi-specialty community provider organisations.

ABHI Innovation Hub Established at Dell Medical School, Texas

As a regular participant of the ABHI Trade Missions to Texas, we are delighted to be part of this exciting development….

The Association of British Healthcare Industries (ABHI) and the Dell Medical School at The University of Texas at Austin are delighted to announce the establishment of the “ABHI Innovation Hub”.

The creation of the Hub, a first for ABHI, will offer UK companies the opportunity to locate themselves at a world-class facility and develop their US business within an ecosystem of clinicians, investors and mentors. It offers companies a compelling office location, providing them the infrastructure to focus on accelerating market access in Texas and beyond.

The Hub will be located within Dell Med’s Health CoLab, a new initiative that provides space and creates connections for start-up companies that share the school’s mission to create healthier communities, starting in Austin and the surrounding area. The Health CoLab directly supports the school, seeking out innovation that promotes health, enhances medical services, increases care resources and access for people in this community in ways that can be scaled to other communities.

“The ABHI Innovation Hub at Dell Medical School will offer UK companies a unique opportunity to collaborate in a truly world class facility,” said Phil Kennedy, Chairman of the ABHI. “The Hub will support promising medical technology innovation whilst looking to develop value based healthcare for the benefit of patients in Texas, throughout the US and at home in the UK.”

The Dell Medical School has a strong focus on supporting health entrepreneurs and businesses. In addition to the CoLab, companies that base themselves in the Innovation Hub will be able to participate in the ‘Texas Health Catalyst,’ a programme designed by the Dell Medical School to foster health research and advance innovation.

“We are very excited to be working with ABHI to strengthen ties between the UK and Austin across a variety of health and technology areas,” said Ruben Rathnasingham, Assistant Dean for Health Product Innovation at Dell Medical School. “We look forward to working with the ABHI, its members and the UK going forward.”

The partnership also extends support to Texas-based companies that are looking to understand and enter the UK healthcare market. Through ABHI’s International Membership scheme, companies looking to introduce innovative medical technology (MedTech) to the UK will be offered insight and market-access knowledge, as well as assistance from a number of partner organisations, including the UK’s Department of International Trade.

“Through this collaboration, companies will be closer to a range of innovation initiatives that we have created and are continuing to create at Dell Med,” said Mellie Price, the school’s Executive Director of Commercialization. “They will find themselves in a rich, creative environment.”